---
title: "Notus BV raises stake in Abeo to 10.51% of capital, 6.56% voting rights"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291794166.md"
description: "Notus BV increased its stake in Abeo to 10.51% of share capital and 6.56% of voting rights on June 9, 2026, through market purchases. The investor concert group holds 63.14% of capital and 66.39% of voting rights. Notus BV indicated potential further acquisitions but stated it does not intend to take control of the company."
datetime: "2026-07-06T11:12:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291794166.md)
  - [en](https://longbridge.com/en/news/291794166.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291794166.md)
generator: "portal-rs"
---

# Notus BV raises stake in Abeo to 10.51% of capital, 6.56% voting rights

-   Notus BV disclosed it crossed above 10% of Abeo’s share capital on June 9, 2026 via market purchases. \* Held 875,860 shares, equal to 10.51% of capital and 6.56% of voting rights. \* Investor concert reported 63.14% of capital and 66.39% of voting rights as of June 9. \* Notus BV signaled potential further buying, said it does not intend to take control. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abeo SA published the original content used to generate this news brief on July 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [ABEO.US](https://longbridge.com/en/quote/ABEO.US.md)

## Related News & Research

- [ABEO Investors Have Opportunity to Join Abeona Therapeutics Inc. Fraud Investigation with SBS Law](https://longbridge.com/en/news/298396132.md)
- [ABEO: ZEVASKYN's launch accelerates with expanding access, strong coverage, and promising patient outcomes](https://longbridge.com/en/news/298466989.md)
- [Abeona Therapeutics director Mark Alvino disposes of 15,000 common shares worth $87,966](https://longbridge.com/en/news/297702333.md)
- [Damartex reports FY2025-26 annual results release available](https://longbridge.com/en/news/298344100.md)
- [Abeona Therapeutics management to present at H.C. Wainwright global investment conference](https://longbridge.com/en/news/297778139.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**